Theranexus (EPA:ALTHX) | WebDisclosure

BRIEF

published on 04/29/2024 at 18:05, 1 year 9 months ago

Theranexus annonce ses résultats annuels 2023 et les avancées de ses projets

Biotechnologie Résultats Financiers 2023 Maladies Rares Theranexus Phase De Recherche
BRIEF

published on 04/29/2024 at 18:05, 1 year 9 months ago

Theranexus announces its 2023 annual results and the progress of its projects

Biotechnology 2023 Financial Results Rare Diseases Theranexus Research Phase
PRESS RELEASE

published on 04/29/2024 at 18:00, 1 year 9 months ago

THERANEXUS PUBLIE SES RESULTATS ANNUELS 2023 ET FAIT LE POINT SUR SES ACTIVITÉS
Theranexus, société biopharmaceutique à lyon, publie ses résultats annuels 2023, sa trésorerie 31 mars 2024 et ses activités. Nouvelle Directrice administrative et financière. Projets innovants dans maladies neurologiques rares

Résultats Annuels Trésorerie Theranexus Maladies Neurologiques Rares Christine Placet
BRIEF

published on 04/26/2024 at 18:05, 1 year 9 months ago

Theranexus publie ses informations sur les droits de vote et le capital pour mars 2024

Droits De Vote Capital Social Biopharmaceutique Theranexus Neurologie
BRIEF

published on 04/26/2024 at 18:05, 1 year 9 months ago

Theranexus releases voting rights and capital information for March 2024

Share Capital Voting Rights Biopharmaceutical Neurology Theranexus
PRESS RELEASE

published on 04/26/2024 at 18:00, 1 year 9 months ago

Information mensuelle relative au nombre total de droits de vote et d'actions composant le capital
Theranexus publie le nombre d'actions et de droits de vote au 31 mars 2024, renforçant sa transparence. Détails sur son engagement dans le traitement des maladies neurologiques rares

Droits De Vote Capital Social Biopharmaceutique Theranexus Maladies Neurologiques Rares
BRIEF

published on 04/23/2024 at 07:35, 1 year 9 months ago

Theranexus, Diverchim et l'INSERM obtiennent un financement de 4.7 millions d'euros pour le développement d'un nouvel oligonucléotide antisens

Financement France 2030 Oligonucléotide Antisens Maladies Rares Neurologiques Autophagie Biothérapies
BRIEF

published on 04/23/2024 at 07:35, 1 year 9 months ago

Theranexus, Diverchim and INSERM obtain funding of 4.7 million euros for the development of a new antisense oligonucleotide

Biothérapies France 2030 Funding Antisense Oligonucleotide Rare Neurological Diseases Autophagy
PRESS RELEASE

published on 04/23/2024 at 07:30, 1 year 9 months ago

Theranexus, Diverchim et l'INSERM bénéficient d'un financement de 4.7 millions d'euros dans le cadre de l'appel à projets " Innovations en Biothérapies et Bioproduction " de France 2030, pour développer un nouvel oligonucléotide antisens
Theranexus, Diverchim, and ARNA laboratory of INSERM receive 4.7 million euros from the French government to develop a groundbreaking autophagy activation therapy called PickASO

Theranexus Diverchim ARNA Laboratory Autophagy Activation Therapy PickASO
PRESS RELEASE

published on 04/23/2024 at 07:30, 1 year 9 months ago

Theranexus, Diverchim and Inserm awarded EUR 4.7 million in funding under the "Innovations in biotherapies and biomanufacturing" call for proposals from France 2030 to develop a novel antisense oligonucleotide
Theranexus, Diverchim, and Inserm's ARNA laboratory receive €4.7 million funding from French Government to develop autophagy activation therapy for rare neurological diseases under the PickASO project in collaboration with France 2030

Theranexus Diverchim Autophagy Activation Therapy Inserm PickASO Project

Published on 02/21/2026 at 00:45, 10 hours 30 minutes ago

Bocana Resources Corp. Extends Letter of Intent on Arizona Mining Claims for Additional Bulk Testing and Assay Review
Published on 02/21/2026 at 00:30, 10 hours 45 minutes ago

Redwood AI Corp. Announces Engagement for IR Services
Published on 02/20/2026 at 23:15, 12 hours ago

DigiPower X Announces Closing of Settlement
Published on 02/20/2026 at 23:00, 12 hours 15 minutes ago

Infinico Metals Corp. Announces Effective Date for 15-for-1 Common Share Consolidation
Published on 02/20/2026 at 22:17, 12 hours 58 minutes ago

Organto Foods Completes Warrant Exercise Incentive Program

View all ACCESSWIRE

Published on 02/20/2026 at 18:36, 16 hours 38 minutes ago

EQS-Adhoc: innoscripta SE: Management Board Proposes Dividend of EUR 4.00 per Share
Published on 02/20/2026 at 18:31, 16 hours 43 minutes ago

Fuller, Smith & Turner PLC: Transaction in own shares
Published on 02/20/2026 at 18:23, 16 hours 51 minutes ago

POS-Transaction in Own Shares
Published on 02/20/2026 at 18:00, 17 hours 14 minutes ago

Leclanché conclut un accord de financement d’un montant de CHF 16,7 millions pour soutenir ses opérations à court terme
Published on 02/20/2026 at 18:00, 17 hours 14 minutes ago

Leclanché Secures Financing Arrangement in the amount of CHF 16.7 million to Support Near-Term Operations

View all EQS

Published on 02/20/2026 at 19:29, 15 hours 45 minutes ago

SFPI GROUP: Liquidity agreement report S2 2025
Published on 02/20/2026 at 19:29, 15 hours 45 minutes ago

SFPI GROUP: bilan du contrat de liquidité S2 S025
Published on 02/20/2026 at 18:00, 17 hours 15 minutes ago

TERACT - Termination of liquidity agreement
Published on 02/20/2026 at 18:00, 17 hours 15 minutes ago

TERACT - Résiliation du contrat de liquidité
Published on 02/20/2026 at 17:35, 17 hours 40 minutes ago

CHIFFRE D'AFFAIRES 2025

View all LES ECHOS COMFI WIRE

News